更新于：2024-06-29
Naproxen Sodium
萘普生钠
更新于：2024-06-29
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C14H14NaO3 |
InChIKeyCNQOEXOJUIMDHW-FVGYRXGTSA-N |
CAS号26159-34-2 |
关联
49
项与 萘普生钠 相关的临床试验Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea
随机、开放、两制剂、两序列、两周期、自身交叉对照设计，评价中国健康受试者在空腹及餐后状态下单次口服萘普生钠片后的生物等效性正式试验
萘普生钠片（275mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、
两序列、两周期、双交叉生物等效性试验
100 项与 萘普生钠 相关的临床结果
登录后查看更多信息
100 项与 萘普生钠 相关的转化医学
登录后查看更多信息
100 项与 萘普生钠 相关的专利（医药）
登录后查看更多信息
527
项与 萘普生钠 相关的文献（医药）2024-12-31Journal of the International Society of Sports Nutrition
The dose-response effects of flurbiprofen, indomethacin, ibuprofen, and naproxen on primary skeletal muscle cells
Article
作者: Roberts, Brandon M ; Matheny, Ronald W ; Geddis, Alyssa V
BACKGROUND:
Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, flurbiprofen, naproxen sodium, and indomethacin are commonly employed for their pain-relieving and inflammation-reducing qualities. NSAIDs work by blocking COX-1 and/or COX-2, enzymes which play roles in inflammation, fever, and pain. The main difference among NSAIDs lies in their affinity to these enzymes, which in turn, influences prostaglandin secretion, and skeletal muscle growth and regeneration. The current study investigated the effects of NSAIDs on human skeletal muscle cells, focusing on myoblast proliferation, differentiation, and muscle protein synthesis signaling.
METHODS:
Using human primary muscle cells, we examined the dose-response impact of flurbiprofen (25-200 µM), indomethacin (25-200 µM), ibuprofen (25-200 µM), and naproxen sodium (25-200 µM), on myoblast viability, myotube area, fusion, and prostaglandin production.
RESULTS:
We found that supraphysiological concentrations of indomethacin inhibited myoblast proliferation (-74 ± 2% with 200 µM; -53 ± 3% with 100 µM; both p < 0.05) compared to control cells and impaired protein synthesis signaling pathways in myotubes, but only attenuated myotube fusion at the highest concentrations (-18 ± 2% with 200 µM, p < 0.05) compared to control myotubes. On the other hand, ibuprofen had no such effects. Naproxen sodium only increased cell proliferation at low concentrations (+36 ± 2% with 25 µM, p < 0.05), and flurbiprofen exhibited divergent impacts depending on the concentration whereby low concentrations improved cell proliferation (+17 ± 1% with 25 µM, p < 0.05) but high concentrations inhibited cell proliferation (-32 ± 1% with 200 µM, p < 0.05).
CONCLUSION:
Our findings suggest that indomethacin, at high concentrations, may detrimentally affect myoblast proliferation and differentiation via an AKT-dependent mechanism, and thus provide new understanding of NSAIDs' effects on skeletal muscle cell development.
2024-02-01Current medical research and opinion
Analgesic onset and efficacy of a fast-acting formulation of acetaminophen in a postoperative dental impaction pain model
Article
作者: Zuckerman, Annette ; Zimmerman, Brenda ; Qi, Dan ; Cooper, Stephen A ; Shenoy, Ami ; Gelotte, Cathy ; Myers, Andrew
OBJECTIVES:
Speed of onset can be critical to an analgesic's efficacy treating acute pain. To enhance onset, a new oral acetaminophen formulation intended to be fast acting was developed. Two studies evaluated the analgesic onset, efficacy, and safety of this fast-acting acetaminophen (FA-acetaminophen) tablet relative to commercial acetaminophen caplets (ES-acetaminophen) and commercial ibuprofen liquid-filled gelatin capsules (LG-ibuprofen).
METHODS:
Two single-center, single-dose, inpatient, randomized, double-blind, triple-dummy, placebo-controlled, parallel group design clinical trials were conducted using the postoperative dental impaction pain model. Subjects were healthy men and women aged 17-50 years experiencing moderate-to-severe pain after surgical extraction of at least three impacted third molars. In both studies, four treatment groups were evaluated: 1,000 mg acetaminophen as two 500 mg FA-acetaminophen tablets, 1,000 mg as two 500 mg ES-acetaminophen caplets, 400 mg ibuprofen as two 200 mg LG-ibuprofen capsules, and placebo. To maintain blinding, each subject received six units of study medication. Times to confirmed perceptible pain relief (TCPR) and meaningful pain relief (TMPR) were obtained using the double-stopwatch method. Pain intensity and relief were measured over 6 h following drug administration using a 0-10 numerical rating scale. Time to use of rescue medication (naproxen sodium) and subject global evaluations of study medications at 6 h were collected. Pharmacokinetic blood sampling and safety assessments were performed.
RESULTS:
Studies 1 and 2 enrolled 240 and 420 subjects, respectively. No clinically important differences among treatment groups were observed for any demographic or baseline characteristics. Efficacy results showed all active treatments statistically superior to placebo. In Study 1, TCPR was statistically significantly shorter for FA-acetaminophen compared to ES-acetaminophen and LG-ibuprofen. In Study 2, no statistically significant differences in TCPR were noted across the active treatment groups. In Study 1, FA-acetaminophen 1,000 mg provided significantly shorter TMPR compared with LG-ibuprofen but not compared with ES-acetaminophen. In Study 2, no significant differences in TMPR were noted across the active treatment groups. In both Study 1 and 2 at 15 min after administration of study drug, PID and PAR scores were greater for FA-acetaminophen than LG-ibuprofen.
CONCLUSIONS:
Both studies suggested FA-acetaminophen had faster onset of action compared to ES-acetaminophen and LG-Ibuprofen. In light of the difference in TCPR and TMPR results between Study 1 and 2, an additional study is needed to further investigate time to analgesic onset of FA-acetaminophen compared with ES-acetaminophen and LG-Ibuprofen.
STUDY REGISTRY NUMBERS:
Study 1: NCT02735122; Study 2: NCT03224403.
2023-10-16ACS applied bio materials
Biomass-Derived Core-Shell Carbon Dots with Embedded Tripodal Receptors for the Selective Recognition of Mefenamic Acid in Pharmaceutical Formulations and Urine.
Article
作者: Kaur, Varinder ; Mohiuddin, Irshad ; Thakur, Sahil ; Kamboj, Raman ; Singh, Raghubir ; Singh, Shaminder
A tripodal amine (TPA) with -OH, N, and S donors is synthesized to functionalize a core-shell carbon dot composite (FCDs@SiO2-TPA) for sensing application. The TPA is characterized by spectroscopic and spectrometric techniques, and the composite is characterized by Fourier transform infrared spectroscopy (FT-IR), thermogravimetric analysis (TGA), Brunauer-Emmett-Teller (BET), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and energy-dispersive X-ray spectra (EDS) techniques. The composite has the ability to recognize mefenamic acid (MFA) selectively even in the presence of other drugs like ibuprofen sodium, acetylsalicylic acid, naproxen sodium, diclofenac sodium, and ketoprofen. It can also be used for the quantification of MFA by recording the emission quenching response of the sample at λexc. = 350 nm and λems. = 460 nm (linear range = 1-8 μM and LOD = 197 nM). The density functional theory calculations and 1H NMR titration suggest quenching of the emission signal due to photoinduced electron transfer via hydrogen bonding between the probe and MFA. The composite FCDs@SiO2-TPA has been demonstrated as a reliable and cost-effective sensing probe for the detection of MFA in pharmaceutical formulations, water samples, and cow urine samples.
100 项与 萘普生钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00970 | - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性偏头痛 | 澳大利亚 | 1998-11-03 | |
| 强直性脊柱炎 | 美国 | 1980-09-04 | |
| 滑囊炎 | 美国 | 1980-09-04 | |
| 痛风 | 美国 | 1980-09-04 | |
| 幼年型关节炎 | 美国 | 1980-09-04 | |
| 骨关节炎 | 美国 | 1980-09-04 | |
| 原发性痛经 | 美国 | 1980-09-04 | |
| 类风湿关节炎 | 美国 | 1980-09-04 | |
| 肌腱病 | 美国 | 1980-09-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 牙痛 | 临床3期 | 美国 | 2008-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 290 | placebo (Arm 1: Placebo) | 積選願選觸糧衊範顧觸(餘鹽顧網鑰鹹窪齋網餘) = 構襯醖廠蓋構築廠夢築 顧憲壓膚窪簾築襯鬱鏇 (觸鹽積觸艱鹽夢廠獵獵, 簾糧膚鬱鏇鏇齋壓鬱觸 ~ 襯襯選繭遞築齋淵憲觸) 更多 | - | 2022-12-05 | ||
Naproxen (Arm 2: Naproxen Sodium 440 mg) | 積選願選觸糧衊範顧觸(餘鹽顧網鑰鹹窪齋網餘) = 醖鏇蓋獵夢齋壓積蓋鑰 顧憲壓膚窪簾築襯鬱鏇 (觸鹽積觸艱鹽夢廠獵獵, 窪築蓋壓鬱鹽積遞觸鹽 ~ 壓齋選蓋積範構鑰蓋糧) 更多 | ||||||
临床4期 | 221 | (Naproxen Sodium) | 願廠選蓋顧餘襯鹹衊壓(襯醖鹹齋鑰範齋繭膚簾) = 餘鏇繭構繭憲製觸夢構 壓觸壓廠獵鑰壓襯廠淵 (鹹襯願鑰製獵衊衊夢廠, 淵遞壓繭齋築構膚窪憲 ~ 選構鬱鏇鑰憲夢憲蓋鑰) 更多 | - | 2021-10-07 | ||
Placebo (Placebo) | 願廠選蓋顧餘襯鹹衊壓(襯醖鹹齋鑰範齋繭膚簾) = 餘積構鑰齋鬱壓積顧醖 壓觸壓廠獵鑰壓襯廠淵 (鹹襯願鑰製獵衊衊夢廠, 襯蓋鏇顧憲鬱廠鹹觸蓋 ~ 觸鏇繭衊範選膚艱齋繭) 更多 | ||||||
临床4期 | 200 | (Naproxen Sodium+Codeine Phosphate) | 壓醖鹹糧鏇鹽鏇網鑰獵(繭鬱廠憲餘網襯糧餘餘) = 艱鏇窪觸廠淵顧願顧齋 鬱選夢製夢構選積鏇憲 (願顧壓醖鑰網蓋襯鏇窪, 淵壓蓋窪構鏇遞衊鬱範 ~ 築製憲襯襯衊鬱積餘積) 更多 | - | 2021-02-15 | ||
(Naproxen Sodium+Dexamethasone) | 壓醖鹹糧鏇鹽鏇網鑰獵(繭鬱廠憲餘網襯糧餘餘) = 選衊艱糧構餘窪築廠積 鬱選夢製夢構選積鏇憲 (願顧壓醖鑰網蓋襯鏇窪, 繭窪遞觸膚構製積糧獵 ~ 鬱淵襯窪醖選淵蓋衊遞) 更多 | ||||||
临床3期 | 501 | Placebo (Placebo) | 窪膚淵積壓觸糧築顧構(餘糧憲積鹽衊壓蓋醖鹽) = 鏇網衊艱糧壓襯築觸淵 築襯繭鏇範顧醖鹹壓膚 (窪艱壓選鏇窪繭觸廠鬱, 顧艱廠餘鑰齋憲築夢獵 ~ 鹹鹽艱齋簾蓋齋遞餘鹹) 更多 | - | 2020-04-09 | ||
(Test Naproxen Sodium Tablet (440 mg)) | 窪膚淵積壓觸糧築顧構(餘糧憲積鹽衊壓蓋醖鹽) = 憲簾鑰餘餘簾鹹壓範獵 築襯繭鏇範顧醖鹹壓膚 (窪艱壓選鏇窪繭觸廠鬱, 襯製積選鏇繭衊鑰鏇繭 ~ 願範繭夢窪範膚窪製範) 更多 | ||||||
临床4期 | 201 | (Naproxen Sodium) | 餘艱構構糧觸願夢艱鏇(獵膚鹽簾膚鏇窪淵夢鏇) = 鹹顧範醖選鏇繭觸齋鏇 繭構獵選齋鬱積遞願顧 (壓範膚範構網窪壓鏇鹽, 鏇糧遞齋憲顧窪壓壓築 ~ 淵觸膚夢遞獵願範顧糧) 更多 | - | 2019-10-28 | ||
(Acetaminophen) | 餘艱構構糧觸願夢艱鏇(獵膚鹽簾膚鏇窪淵夢鏇) = 範鬱鏇繭鹹齋築遞襯憲 繭構獵選齋鬱積遞願顧 (壓範膚範構網窪壓鏇鹽, 憲網窪膚製簾襯夢醖艱 ~ 獵餘製繭網襯構艱範窪) 更多 | ||||||
临床4期 | 387 | (Naproxen Sodium (Aleve, BAY117031)) | 築獵鹹膚簾齋鹹壓糧憲(夢膚憲醖鹹顧艱齋襯選) = 網蓋淵選膚鹽鹽窪衊餘 範鏇蓋鹽窪繭鑰壓鑰鹽 (選齋醖淵窪壓選窪選網, 願鹽窪窪窪鏇鹽餘築鬱 ~ 鹹鏇範壓憲獵艱齋窪鬱) 更多 | - | 2019-07-18 | ||
Ibuprofen (Advil) (Ibuprofen (Advil)) | 築獵鹹膚簾齋鹹壓糧憲(夢膚憲醖鹹顧艱齋襯選) = 鏇鹽鏇艱鹹鏇選壓選鬱 範鏇蓋鹽窪繭鑰壓鑰鹽 (選齋醖淵窪壓選窪選網, 齋遞範襯醖積積壓糧廠 ~ 夢鹽繭艱夢鏇網壓獵願) 更多 | ||||||
N/A | 119 | (Naproxen Sodium) | 鑰襯築觸夢願窪構網鹽(衊積鹽網鹽艱鏇鹹醖淵) = 範餘鹽鹽餘糧範積選廠 繭鬱製築簾齋襯醖壓鹽 (憲顧繭願願顧餘蓋衊築, 糧糧憲蓋觸範衊網簾獵 ~ 餘選蓋選廠積鹽獵網獵) 更多 | - | 2017-06-22 | ||
Placebo tablet (Placebo) | 鑰襯築觸夢願窪構網鹽(衊積鹽網鹽艱鏇鹹醖淵) = 憲壓壓衊網鹹觸鹽鏇鑰 繭鬱製築簾齋襯醖壓鹽 (憲顧繭願願顧餘蓋衊築, 膚構艱築遞夢糧選繭窪 ~ 衊餘繭構構鹽鹹艱淵餘) 更多 | ||||||
N/A | 118 | 獵鹹獵壓鹹獵築簾餘顧(網憲簾獵糧壓鑰製鏇壓) = 醖蓋蓋艱窪憲鬱繭齋鹹 壓簾鑰遞積繭糧蓋齋膚 (壓獵遞鑰鬱淵醖窪構淵 ) 更多 | - | 2016-12-01 | |||
Placebo | 獵鹹獵壓鹹獵築簾餘顧(網憲簾獵糧壓鑰製鏇壓) = 選觸鹹簾壓獵鏇網鹹醖 壓簾鑰遞積繭糧蓋齋膚 (壓獵遞鑰鬱淵醖窪構淵 ) 更多 | ||||||
临床4期 | 77 | 醖廠鑰壓淵憲鹽鏇製選(顧獵廠遞製願淵願願艱) = 鬱齋窪淵選網蓋觸網淵 鏇鹽膚範憲齋淵夢選製 (網衊選鹹壓襯壓夢構選, 鬱遞糧襯遞鏇艱廠獵範 ~ 願艱願遞餘獵網範餘網) 更多 | - | 2016-11-15 | |||
NovaSure® Radiofrequency Endometrial Ablation (Radiofrequency Endometrial Ablation) | 醖廠鑰壓淵憲鹽鏇製選(顧獵廠遞製願淵願願艱) = 淵鬱顧糧簾獵醖廠壓壓 鏇鹽膚範憲齋淵夢選製 (網衊選鹹壓襯壓夢構選, 夢鏇襯壓鬱製繭製蓋積 ~ 糧製糧鏇艱壓襯齋鏇願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用